Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'
Portfolio Pulse from Avi Kapoor
Jim Cramer shared his views on several stocks during CNBC's 'Mad Money Lightning Round.' He recommended buying Recursion Pharmaceuticals (RXRX) and praised its recent financial results. Cramer was not optimistic about Corning (GLW) and advised against buying it. He was also not supportive of Intuitive Machines (LUNR) and suggested holding off on Axon Enterprise (AXON) despite its strong earnings. Cramer was positive about Kratos Defense & Security Solutions (KTOS) and Merit Medical Systems (MMSI), both of which reported strong quarterly results.
May 23, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jim Cramer advised against buying Corning, citing its inability to generate desired returns. Mizuho analyst also gave it a Neutral rating with a $36 price target.
Cramer's negative outlook and the Neutral rating from Mizuho are likely to dampen investor sentiment, potentially leading to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Jim Cramer expressed a lack of confidence in Intuitive Machines, which recently reported a significant Q1 GAAP loss.
Cramer's lack of confidence and the company's significant Q1 loss are likely to negatively impact investor sentiment, leading to a potential short-term decline in the stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Jim Cramer suggested holding off on Axon Enterprise despite its strong Q1 earnings, which beat market estimates.
Despite strong Q1 earnings, Cramer's cautious stance may lead to mixed investor reactions, resulting in a neutral short-term impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Jim Cramer recommended staying invested in Kratos Defense & Security Solutions and even buying more, following its strong Q1 results.
Cramer's positive recommendation and the company's strong Q1 results are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
Jim Cramer described Merit Medical Systems as 'good' following its upbeat Q1 results.
Cramer's positive comment and the company's strong Q1 results are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Jim Cramer recommended buying Recursion Pharmaceuticals, calling it a 'terrific spec' after the company reported better-than-expected Q1 results.
Cramer's positive recommendation and the company's strong Q1 results are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100